
==== Front
Bone Marrow Transplant
Bone Marrow Transplant
Bone Marrow Transplantation
0268-3369
1476-5365
Nature Publishing Group UK London

38909123
2333
10.1038/s41409-024-02333-z
Correspondence
Monocytosis as prognostic factor for chronic graft versus host disease
Marrero-Cepeda C. 1
http://orcid.org/0000-0001-7487-3793
Caballero-Velazquez T. 1
Garcia-Canale S. 1
Martin-Dominguez F. 1
Rodriguez-Torres N. 1
Espigado-Tocino I. 1
Blazquez-Goñi C. 1
Andrade-Ruiz H. 2
http://orcid.org/0000-0003-3616-6101
Perez-Simon J. josea.perez.simon.sspa@juntadeandalucia.es

1
1 grid.9224.d 0000 0001 2168 1229 Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS), CSIC, University of Seville, Seville, Spain
2 https://ror.org/02mcpvv78 FISEVI, University Hospital Virgen del Rocio, Seville, Spain
22 6 2024
22 6 2024
2024
59 9 13261328
11 3 2024
10 6 2024
14 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Subject terms

Risk factors
Haematological cancer
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcTo the Editor:

Chronic graft versus host disease (cGvHD) is the main cause of long-term morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT) [1].

Several biomarkers have been described which predict the risk of acute GvHD (aGvHD) and its severity. In this regard, suppressor of tumorigenicity-2 (ST2) and regenerating islet-derived protein 3-α (REG3α) predict the risk for aGvHD and GvHD-related mortality (NRM) [2] according to the Mount Sinai Acute GVHD International Consortium (MAGIC) [3, 4]. By contrast, no cGvHD prognostic biomarkers have been clearly stablished during follow up.

Finding a prognostic biomarker for cGvHD onset is an unmet need in clinical practice. A biomarker could be used to guide prophylaxis treatments and follow-up strategies. High-risk patients could stay longer with high-dose immunosuppressive therapy, change the prophylaxis regimen to a more intensive one or targeting another pathway or mechanism of action. When identifying a biomarker, it is to take into account its sensitivity and specificity; particularly the latter in order to avoid false positive cases which might lead to non-justified treatments.

Considering the important role of monocytes in cGvHD pathophysiology, we analyzed the potential role of monocytosis as cGvHD biomarker.

We performed a retrospective study including patients who received allogeneic HSCT in our center between 2014 and 2017. We excluded patients who died within the first 100 days post-transplant. Overall, 135 patients were included into the analysis. Monocytes were analyzed from transplantation until death or last follow-up. We only considered as prognostic factor the monocytosis that appeared within 6 months before the diagnosis of cGvHD.

Cumulative incidence (CI) of cGvHD of patients at risk at 36 months was 66.9% (range 56.7–74.7%), with a CI of moderate-severe of 52.3% (range 40.7–61.6%) and severe of 29.1% (range 18.5–38.4%). Overall survival (OS) at 36 months was 60.7% (range 51–72.2%) and the CI of relapse at 36 months was 36.3% (range 24.6–46.2%).

Interestingly, post-transplant monocytes count highly correlated with the risk of cGvHD. The most significant results were observed at ≥6 months post-transplantation. Median monocyte count was 1.0 ×109 / L among patients who subsequently developed cGvHD as compared to 0.695 ×109 / L among those who did not (p = 0.00067). The most prognostic cut-off value in the ROC curve was ≥0.84 ×109/L, but a cut-off value of ≥1.0 ×109/L was also highly prognostic and, therefore, it was used in the study (Fig. 1a). With this cut-off value at ≥6 months post-transplantation, the risk of cGvHD at 36 months was 74.6% (range: 56.6–85.19%) vs 41.8% (range: 27.1–53.5%) for patients with more or less than 1.0 ×109/L monocytes (p = 0.0004) (Fig. 1b). cGvHD flared at a median of 19 months in patients with >1.0 ×109/L monocytes and it was not reached during follow-up in patients with lower counts (p = 0.0004).Fig. 1 Monocytosis as prognostic factor for cGvHD: ROC curve and cumulative incidence (CI).

a ROC curve. The most predictive value was 0.84 × 109/L monocytes, with a sensitivity of 73% and a specificity of 67%. Cut-off of 1.0 × 109/L monocytes was also an optimal value with a sensitivity of 59.3% and a specificity of 78.8%. b CI of overall cGvHD at ≥6 months after alloHSCT among patients with more or less than 1.0 × 109/L monocytes. c CI of moderate-severe cGvHD and d CI of severe cGvHD, also among patients with more or less than 1.0 × 109/L monocytes.

Moreover, monocyte count was highly prognostic not only for the incidence but also for cGvHD severity: CI of moderate-severe cGvHD at 36 months were 64.7% (range 43.9–77.82%) vs 27.3% (14.2–38.4%), among patients with and without monocytosis, respectively (p = 0.00046) (Fig. 1c) while these values for severe cGvHD were 41.6% (range 21–56.9%) vs 11.4% (range 2.3–19.7%) (p = 0.0077) (Fig. 1d).

Finally, we performed a multivariate analysis for overall cGvHD including monocytes count, GvHD prophylaxis, donor type, HLA matched and prior aGvHD. Patients with ≥1.0 ×109/L monocytes during follow-up had a HR to develop cGvHD 2.1 times higher than those with a lower count (p = 0.006). Similarly, the risk to develop moderate-severe cGvHD was 2.93 times higher among patients with ≥1.0 ×109/L monocytes as compared to those with lower counts (p = 0.001).

A competing risks model was performed to further evaluate the impact of monocytes count on the incidence of overall cGvHD: 66.99% vs 36.53% for patients with or without monocytes >1.0 ×109 / L developed it. Using a Fine-Gray regression, patients with monocytosis had 2.39 greater risk of developing overall cGvHD (p = 0.0029).

Reviews by Crossland et al. and Giaccone et al. analyzed immune cells, alloantibodies, glycans, microRNA, extracellular vesicles, endothelial-derived microparticles, DNA methylation and microbiome changes as potential cGvHD biomarkers [5, 6] CD19+ CD21− B cells are increased in patients with first diagnosis of cGvHD and they could predict higher risk of BOS [7–9]. Elevated Th17 T cells have also been reported in blood or target organs of cGvHD patients [10–14]. Furthermore, early CD8+ T-cell recovery on day 28 after HSCT could predict lower risk of relapse but higher of GvHD.

Pan et al. suggested that anti-HLA antibodies could be a prognostic biomarker for cGvHD [15]. Also, microRNA has been widely studied in aGvHD with limited evidence for cGvHD. However, a study in mice showed a miR-17–92 role in scleroderma and BOS [16] and Lacina et al. studied altered microRNA profile in extracellular vesicles in cGvHD patients three months after transplantation [17].

Chirumbolo et al. created a multiparameter prognostic risk score of cGvHD including previous aGvHD (P = 0.007), CXCL10 serum concentrations (P = 0.008) and plasmacytoid dendritic cell peripheral levels (P < 0.001) at 3 months after HSCT, with promising results that need to be validated [18]. As the options described above, these biomarkers are not easily applicable in clinical practice. This is also the inconvenience for biomarkers proposed by Kordelas et al.: decreased Programmed Cell Death Protein 1 (PD-1) levels [19] and low soluble HLA-E levels [20]. A more accessible biomarker in any routine lab would be prolactin and, in this regard, a study by Salas et al. found out that hyperprolactinemia was related to cGvHD activity [21].

In cGvHD pathophysiology, immune cell populations are altered, including monocytes. Stimulated monocytes produce IL-1 and TNFα. Dendritic cells are activated by TNFα leading to increased alloantigen presentation, inflammatory chemokines production, immune cells migration to affected organs and tissue damage due to apoptosis and necrosis [22, 23]. A study performed by Arpinati et al. showed that marrow and blood monocytes were increased and activated in patients with cGvHD when compared to those without (P = 0.006) [24]. Moreover, promising data have been reported using Axatilimab, which targets CSF-1R expressed in monocytes, among patients with cGvHD which failed previous lines of therapy [25]. CCR2+ monocytes generate monocyte-derived alveolar macrophages, leading to the development of alloimmunity and bronchiolitis obliterans syndrome, which are both involved in cGvHD [26].

Monocytes’ count would be an excellent biomarker due to its accessibility. By contrast, most biomarkers previously identified are time consuming and/or difficult to obtain [27].

Our findings suggest that monocytosis may influence clinical decisions, possibly with a positive impact in early diagnosis. The role of biomarkers in adjusting immunosuppressive therapies, prognosis and outcomes of the disease is unknown, but it is clearly a promising field of investigation. It would also be important to take into consideration other factors that might cause monocytosis in order to avoid false positives and unnecessary treatments.

In conclusion, monocytosis onset from 6 months after allo-HSCT is a highly prognostic biomarker of cGvHD. Monocytes’ count ≥1.0 109/L may identify patients with higher risk of cGvHD, particularly those with moderate and severe manifestations.

Further investigations are needed to apply these findings on developing personalized approaches for cGvHD management.

Author contributions

CM-C and JAP-S wrote the original draft, reviewed, and edited the manuscript. TC-V, SG-C, FM-D, NR-T, IE-T, CB-G reviewed the manuscript. HA-R performed the statistical analysis.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Hamilton BK Updates in Chronic Graft-versus-Host Disease Hematol Am Soc Hematol Educ Program 2021 2021 648 54 10.1182/HEMATOLOGY.2021000301
Hamilton BK. Updates in Chronic Graft-versus-Host Disease. Hematol Am Soc Hematol Educ Program. 2021;2021:648–54. 10.1182/HEMATOLOGY.2021000301.10.1182/HEMATOLOGY.2021000301
2. Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, et al. An Early-Biomarker Algorithm Predicts Lethal Graft-versus-Host Disease and Survival. JCI Insight. 2017;2. 10.1172/JCI.INSIGHT.89798.
3. Major-Monfried H Renteria AS Pawarode A Reddy P Ayuk F Holler E MAGIC Biomarkers Predict Long-Term Outcomes for Steroid-Resistant Acute GVHD Blood 2018 131 2846 55 10.1182/BLOOD-2018-01-822957 29545329
Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC Biomarkers Predict Long-Term Outcomes for Steroid-Resistant Acute GVHD. Blood. 2018;131:2846–55. 10.1182/BLOOD-2018-01-822957.29545329 10.1182/BLOOD-2018-01-822957
4. Levine JE Braun TM Harris AC Holler E Taylor A Miller H A Prognostic Score for Acute Graft-versus-Host Disease Based on Biomarkers: A Multicentre Study Lancet Haematol 2015 2 e21 e29 10.1016/S2352-3026(14)00035-0 26687425
Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A Prognostic Score for Acute Graft-versus-Host Disease Based on Biomarkers: A Multicentre Study. Lancet Haematol. 2015;2:e21–e29. 10.1016/S2352-3026(14)00035-0.26687425 10.1016/S2352-3026(14)00035-0
5. Crossland RE, Perutelli F, Bogunia-Kubik K, Mooney N, Milutin Gašperov N, Pučić-Baković M, et al. Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease. Front Immunol. 2020;11. 10.3389/FIMMU.2020.602547.
6. Giaccone L, Faraci DG, Butera S, Lia G, Di Vito C, Gabrielli G, et al. Biomarkers for Acute and Chronic Graft versus Host Disease: State of the Art. Expert Rev Hematol. 2020;14:79–96. 10.1080/17474086.2021.1860001.
7. Greinix HT Kuzmina Z Weigl R Körmoczi U Rottal A Wolff D CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease Biol Blood Marrow Transpl 2015 21 250 8 10.1016/J.BBMT.2014.11.010
Greinix HT, Kuzmina Z, Weigl R, Körmoczi U, Rottal A, Wolff D, et al. CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2015;21:250–8. 10.1016/J.BBMT.2014.11.010.10.1016/J.BBMT.2014.11.010
8. Kuzmina Z Krenn K Petkov V Körmöczi U Weigl R Rottal A CD19(+)CD21(Low) B Cells and Patients at Risk for NIH-Defined Chronic Graft-versus-Host Disease with Bronchiolitis Obliterans Syndrome Blood 2013 121 1886 95 10.1182/BLOOD-2012-06-435008 23303823
Kuzmina Z, Krenn K, Petkov V, Körmöczi U, Weigl R, Rottal A, et al. CD19(+)CD21(Low) B Cells and Patients at Risk for NIH-Defined Chronic Graft-versus-Host Disease with Bronchiolitis Obliterans Syndrome. Blood. 2013;121:1886–95. 10.1182/BLOOD-2012-06-435008.23303823 10.1182/BLOOD-2012-06-435008
9. Greinix HT Pohlreich D Kouba M Körmöczi U Lohmann I Feldmann K Elevated Numbers of Immature/Transitional CD21- B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host Disease Biol Blood Marrow Transpl 2008 14 208 19 10.1016/J.BBMT.2007.10.009
Greinix HT, Pohlreich D, Kouba M, Körmöczi U, Lohmann I, Feldmann K, et al. Elevated Numbers of Immature/Transitional CD21- B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2008;14:208–19. 10.1016/J.BBMT.2007.10.009.10.1016/J.BBMT.2007.10.009
10. Brüggen MC Klein I Greinix H Bauer W Kuzmina Z Rabitsch W Diverse T-Cell Responses Characterize the Different Manifestations of Cutaneous Graft-versus-Host Disease Blood 2014 123 290 9 10.1182/BLOOD-2013-07-514372 24255916
Brüggen MC, Klein I, Greinix H, Bauer W, Kuzmina Z, Rabitsch W, et al. Diverse T-Cell Responses Characterize the Different Manifestations of Cutaneous Graft-versus-Host Disease. Blood. 2014;123:290–9. 10.1182/BLOOD-2013-07-514372.24255916 10.1182/BLOOD-2013-07-514372
11. Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, et al. An Activated Th17-Prone T Cell Subset Involved in Chronic Graft-versus-Host Disease Sensitive to Pharmacological Inhibition. JCI Insight. 2017;2. 10.1172/JCI.INSIGHT.92111.
12. Dander E Balduzzi A Zappa G Lucchini G Perseghin P André V Interleukin-17-Producing T-Helper Cells as New Potential Player Mediating Graft-versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation Transplantation 2009 88 1261 72 10.1097/TP.0B013E3181BC267E 19996925
Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, André V, et al. Interleukin-17-Producing T-Helper Cells as New Potential Player Mediating Graft-versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. Transplantation. 2009;88:1261–72. 10.1097/TP.0B013E3181BC267E.19996925 10.1097/TP.0B013E3181BC267E
13. Hill GR Olver SD Kuns RD Varelias A Raffelt NC Don AL Stem Cell Mobilization with G-CSF Induces Type 17 Differentiation and Promotes Scleroderma Blood 2010 116 819 28 10.1182/BLOOD-2009-11-256495 20435882
Hill GR, Olver SD, Kuns RD, Varelias A, Raffelt NC, Don AL, et al. Stem Cell Mobilization with G-CSF Induces Type 17 Differentiation and Promotes Scleroderma. Blood. 2010;116:819–28. 10.1182/BLOOD-2009-11-256495.20435882 10.1182/BLOOD-2009-11-256495
14. Chen X Vodanovic-Jankovic S Johnson B Keller M Komorowski R Drobyski WR Absence of Regulatory T-Cell Control of TH1 and TH17 Cells Is Responsible for the Autoimmune-Mediated Pathology in Chronic Graft-versus-Host Disease Blood 2007 110 3804 13 10.1182/BLOOD-2007-05-091074 17693581
Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of Regulatory T-Cell Control of TH1 and TH17 Cells Is Responsible for the Autoimmune-Mediated Pathology in Chronic Graft-versus-Host Disease. Blood. 2007;110:3804–13. 10.1182/BLOOD-2007-05-091074.17693581 10.1182/BLOOD-2007-05-091074
15. Pan Z Yuan X Li Y Wu X Zhu W Bao X Dynamic Detection of Anti-Human Leukocyte Antigen (HLA) Antibodies but Not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall Survival in HLA 12/12-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies Biol Blood Marrow Transpl 2016 22 86 95 10.1016/J.BBMT.2015.08.015
Pan Z, Yuan X, Li Y, Wu X, Zhu W, Bao X, et al. Dynamic Detection of Anti-Human Leukocyte Antigen (HLA) Antibodies but Not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall Survival in HLA 12/12-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Biol Blood Marrow Transpl. 2016;22:86–95. 10.1016/J.BBMT.2015.08.015.10.1016/J.BBMT.2015.08.015
16. Wu Y Schutt S Paz K Zhang M Flynn RP Bastian D MicroRNA-17-92 Is Required for T-Cell and B-Cell Pathogenicity in Chronic Graft-versus-Host Disease in Mice Blood 2018 131 1974 86 10.1182/BLOOD-2017-06-789321 29530952
Wu Y, Schutt S, Paz K, Zhang M, Flynn RP, Bastian D, et al. MicroRNA-17-92 Is Required for T-Cell and B-Cell Pathogenicity in Chronic Graft-versus-Host Disease in Mice. Blood. 2018;131:1974–86. 10.1182/BLOOD-2017-06-789321.29530952 10.1182/BLOOD-2017-06-789321
17. Łacina P Crossland RE Wielińska J Czyż A Szeremet A Ussowicz M Differential Expression of MiRNAs from Extracellular Vesicles in Chronic Graft-versus-Host Disease: A Preliminary Study Adv Clin Exp Med 2023 32 539 44 10.17219/ACEM/155373 36398373
Łacina P, Crossland RE, Wielińska J, Czyż A, Szeremet A, Ussowicz M, et al. Differential Expression of MiRNAs from Extracellular Vesicles in Chronic Graft-versus-Host Disease: A Preliminary Study. Adv Clin Exp Med. 2023;32:539–44. 10.17219/ACEM/155373.36398373 10.17219/ACEM/155373
18. Chirumbolo G Dicataldo M Barone M Storci G De Matteis S Laprovitera N A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation Transpl Cell Ther 2023 29 302.e1 302 10.1016/J.JTCT.2023.02.008
Chirumbolo G, Dicataldo M, Barone M, Storci G, De Matteis S, Laprovitera N, et al. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation. Transpl Cell Ther. 2023;29:302.e1–302. 10.1016/J.JTCT.2023.02.008.10.1016/J.JTCT.2023.02.008
19. Kordelas L, Buttkereit U, Heinemann FM, Horn PA, Giebel B, Beelen DW, et al. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival. Front Immunol. 2021;12. 10.3389/FIMMU.2021.694843.
20. Kordelas L, Schwich E, Lindemann M, Heinemann FM, Buttkereit U, Horn PA, et al. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival. Front Immunol. 2020;10. 10.3389/FIMMU.2019.03027.
21. Salas MQ Ezzat S Lam W Law AD Pasic I Michelis FV Prolactin, a Potential Biomarker for Chronic GVHD Activity Eur J Haematol 2021 106 158 64 10.1111/EJH.13531 33047394
Salas MQ, Ezzat S, Lam W, Law AD, Pasic I, Michelis FV, et al. Prolactin, a Potential Biomarker for Chronic GVHD Activity. Eur J Haematol. 2021;106:158–64. 10.1111/EJH.13531.33047394 10.1111/EJH.13531
22. Zeiser R Blazar BR Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets N Engl J Med 2017 377 2565 79 10.1056/NEJMRA1703472 29281578
Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377:2565–79. 10.1056/NEJMRA1703472.29281578 10.1056/NEJMRA1703472
23. Martinez-Cibrian N, Zeiser R, Perez-Simon JA. Graft-versus-Host Disease Prophylaxis: Pathophysiology-Based Review on Current Approaches and Future Directions. Blood Rev. 2021;48. 10.1016/J.BLRE.2020.100792.
24. Arpinati M Chirumbolo G Marzocchi G Baccarani M Rondelli D Increased Donor CD86+CD14+ Cells in the Bone Marrow and Peripheral Blood of Patients with Chronic Graft-versus-Host Disease Transplantation 2008 85 1826 32 10.1097/TP.0B013E3181788A84 18580477
Arpinati M, Chirumbolo G, Marzocchi G, Baccarani M, Rondelli D. Increased Donor CD86+CD14+ Cells in the Bone Marrow and Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Transplantation. 2008;85:1826–32. 10.1097/TP.0B013E3181788A84.18580477 10.1097/TP.0B013E3181788A84
25. Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, et al. Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201). Blood. 2023;142:1.
26. Liu Z, Liao F, Zhu J, Zhou D, Heo GS, Leuhmann HP, et al. Reprogramming Alveolar Macrophage Responses to TGF-β Reveals CCR2+ Monocyte Activity That Promotes Bronchiolitis Obliterans Syndrome. J Clin Invest. 2022;132. 10.1172/JCI159229.
27. Kitko CL Pidala J Schoemans HM Lawitschka A Flowers ME Cowen EW National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report Transpl Cell Ther 2021 27 545 57 10.1016/J.JTCT.2021.03.033
Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transpl Cell Ther. 2021;27:545–57. 10.1016/J.JTCT.2021.03.033.10.1016/J.JTCT.2021.03.033
